Histone deacetylase inhibitors providing an epigenetic treatment in cancer

Cancer is among the leading causes of death worldwide and therefore one diseases in which there have been major medical advances focus researchers. Drugs used cancer treatment affect rapidly proliferating normal cells as well cells. In recent years, targeted therapy has provided by identifying specific pathways Epigenetic mechanisms are therapies treatment. regulators ensure continuity process inducing epigenetic changes through such DNA methylation, histone post-translational modifications, non-coding RNA regulation. Histone deacetylases (HDACs), involved transcription-independent events repair mitosis, enzymes that remove acetyl groups attached to lysine residue amino terminal tails histones. deacetylase inhibitors (HDACIs) provide cancer, play a key role balance between acetylation deacetylation histone, extensively studied Today, four HDACIs on market approved FDA (Food Drug Administration) combinations these drugs with agents show anticancer activity different being studied. Promising results obtained from combinations, further studies ongoing hybrid derivatives certain various stages.